Advertisement
ABBV vs NVS
Which Stock Would AI Choose? AbbVie (ABBV) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- AbbVie (ABBV) boasts a larger market capitalization of approximately $351 billion and higher year-to-date returns of 11.61%, outperforming Novartis (NVS)'s 8.06%.
- NVS exhibits stronger profitability with a 24.67% profit margin and 30.81% return on equity (ROE, a measure of profitability relative to shareholders' equity), compared to ABBV's lower net income margins.
- Both stocks offer attractive dividend yields around 3.3-3.5%, appealing to income-focused investors, though ABBV's payout ratio exceeds 276% while NVS's is a more sustainable 55.86%.
- Recent weeks saw ABBV face a U.S. FDA complete response letter (CRL, a request for additional information) on a new drug application, contributing to downward pressure, while NVS gained from positive European regulatory opinions.
- NVS trades at a more reasonable trailing P/E of 20.35 versus ABBV's elevated 83.84, reflecting differences in earnings profiles.
Introduction
AbbVie (ABBV) and Novartis (NVS), two leading biopharmaceutical giants, offer investors exposure to innovative therapies in immunology, oncology, and beyond. This comparison is particularly relevant for dividend-seeking traders navigating patent cliffs and regulatory hurdles, as well as growth-oriented investors eyeing pipeline momentum. With similar yields and sector risks, understanding their relative performance, valuations, and recent catalysts helps assess positioning in a volatile healthcare market dominated by drug approvals and biosimilar competition.
ABBV Overview and Recent Performance
AbbVie (ABBV), a U.S.-based biopharmaceutical firm, specializes in immunology, oncology, neuroscience, and aesthetics. Its portfolio features blockbusters like Skyrizi and Rinvoq, which have driven growth amid the ongoing erosion of former flagship Humira due to biosimilar entry. In recent market activity, ABBV shares have traded around $199, down from peaks near $245 in the past year, reflecting broader sector pressures and a dip below the 50-day simple moving average (SMA, a technical indicator of short-term trend). Sentiment has been tempered by a U.S. FDA complete response letter on its trenibotulinumtoxinE application citing manufacturing issues, alongside post-earnings consolidation. Year-to-date gains stand at 11.61%, supported by 10% quarterly revenue growth, though trailing earnings reflect one-time charges.
NVS Overview and Recent Performance
Novartis (NVS), a Swiss multinational, focuses on innovative medicines across cardiovascular, oncology, neuroscience, immunology, and gene therapies following its generics spin-off. Key products include Entresto and Kisqali. Shares have hovered near $145 in recent weeks, within a 52-week range of $105 to $170, with year-to-date returns of 8.06% and a robust one-year gain of 36%. Positive sentiment stems from European Medicines Agency (EMA) endorsements, including a CHMP positive opinion for its spinal muscular atrophy gene therapy Itvisma and WHO prequalification for infant malaria treatment Coartem Baby. These developments bolster pipeline confidence amid 9.57% revenue growth, though shares have softened slightly in line with market trends.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 performers from its library of over 350 AI trading bots, each employing unique strategies across thousands of tickers. These curated bots adapt to current market conditions, featuring annualized returns ranging from +15% to +168%, win rates of 48% to 88%, and trade durations from minutes to weeks. Examples include semiconductor-focused bots with +70% to +103% returns and 59-72% win rates, or volatility plays exceeding +100%. Diverse styles—scalping, swing, or pattern-based—cater to varying risk appetites. Traders can explore these high-conviction signals to enhance strategies amid fluctuating pharma sentiment.
Head-to-Head Comparison
AbbVie (ABBV) and Novartis (NVS) both anchor the biopharma sector but diverge in scale and focus: ABBV emphasizes U.S. immunology dominance post-Humira, while NVS leverages global diversification in gene therapies and rare diseases. Growth drivers contrast—ABBV relies on Skyrizi/Rinvoq uptake versus patent losses, versus NVS's steady 10%+ revenue expansion. Recent momentum favors neither decisively, with ABBV showing YTD strength but regulatory setbacks, and NVS one-year outperformance amid approvals. Risk factors include pipeline delays and biosimilars for both, though ABBV's higher leverage contrasts NVS's balance sheet stability. Market sentiment tilts toward NVS for valuation (lower P/E) and margins, while ABBV appeals for size and yield sustainability trade-offs.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward Novartis (NVS) with moderate conviction, citing superior profitability metrics, a more attractive trailing P/E ratio, recent positive regulatory catalysts, and relative stability versus AbbVie’s (ABBV) elevated payout and FDA hurdles. While ABBV offers YTD edge and dividend appeal, NVS aligns better with trend consistency and risk-reward in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and NVS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 5 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- ABBV’s FA Score: 5 green, 0 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 4 bearish.
- NVS’s TA Score: 6 bullish, 3 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +0.22% price change this week, while NVS (@Pharmaceuticals: Major) price change was +2.62% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +6.56%, and the average quarterly price growth was +4.69%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
NVS is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | NVS | ABBV / NVS | |
| Capitalization | 402B | 291B | 138% |
| EBITDA | 16.9B | 22.4B | 75% |
| Gain YTD | 1.303 | 14.380 | 9% |
| P/E Ratio | 111.63 | 21.93 | 509% |
| Revenue | 62.8B | 56.6B | 111% |
| Total Cash | 9.39B | 6.98B | 135% |
| Total Debt | 72.9B | 47B | 155% |
ABBV | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 11 | 6 | |
SMR RATING 1..100 | 1 | 27 | |
PRICE GROWTH RATING 1..100 | 33 | 47 | |
P/E GROWTH RATING 1..100 | 26 | 36 | |
SEASONALITY SCORE 1..100 | 3 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (6) in the Pharmaceuticals Major industry is in the same range as ABBV (11). This means that NVS’s stock grew similarly to ABBV’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as ABBV (11). This means that NVS’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as NVS (27). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's Price Growth Rating (33) in the Pharmaceuticals Major industry is in the same range as NVS (47). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
ABBV's P/E Growth Rating (26) in the Pharmaceuticals Major industry is in the same range as NVS (36). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.
| ABBV | NVS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 37% | N/A |
| Stochastic ODDS (%) | 2 days ago 45% | 2 days ago 39% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 49% |
| MACD ODDS (%) | N/A | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 53% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 48% |
| Advances ODDS (%) | 9 days ago 57% | 9 days ago 51% |
| Declines ODDS (%) | 3 days ago 48% | 12 days ago 45% |
| BollingerBands ODDS (%) | 2 days ago 33% | 2 days ago 54% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 45% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.